CRISPR Therapeutics AG
General ticker "CRSP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.6B (TTM average)
CRISPR Therapeutics AG follows the US Stock Market performance with the rate: 24.5%.
Estimated limits based on current volatility of 3.8%: low 51.82$, high 55.89$
Factors to consider:
- Total employees count: 393 as of 2024
- Top business risk factors: Insufficient funding, Gene editing technology risks, Supply chain disruptions, Geopolitical risks, Intellectual property risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [38.44$, 81.91$]
- 2026-12-31 to 2027-12-31 estimated range: [29.72$, 66.50$]
Financial Metrics affecting the CRSP estimates:
- Negative: with PPE of -10.2 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Shareholder equity ratio, % of 84.84 > 64.29
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: -4.41 < Investing cash flow per share per price, % of -0.64
Short-term CRSP quotes
Long-term CRSP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $371.21MM | $37.31MM | $3.51MM |
| Operating Expenses | $593.74MM | $503.88MM | $668.08MM |
| Operating Income | $-222.54MM | $-466.57MM | $-664.57MM |
| Non-Operating Income | $71.82MM | $103.90MM | $86.61MM |
| R&D Expense | $387.33MM | $320.65MM | $381.06MM |
| Income(Loss) | $-150.72MM | $-362.67MM | $-577.97MM |
| Taxes | $2.89MM | $3.59MM | $3.63MM |
| Net Income(Loss)* | $-153.61MM | $-366.25MM | $-581.60MM |
| Stockholders Equity | $1,882.80MM | $1,932.08MM | $1,921.81MM |
| Assets | $2,229.57MM | $2,242.03MM | $2,265.24MM |
| Operating Cash Flow | $-260.38MM | $-142.77MM | $-345.01MM |
| Capital expenditure | $9.47MM | $1.90MM | $0.91MM |
| Investing Cash Flow | $374.65MM | $-280.48MM | $-31.80MM |
| Financing Cash Flow | $62.66MM | $331.98MM | $426.03MM |
| Earnings Per Share** | $-1.94 | $-4.34 | $-6.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.